Physician profile
Angela Gill
NPI 1952894578
$9,161.14
in general payments reported to CMS, 2019-2025
11 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,052 · 2022: $2,109 · 2023: $2,213 · 2024: $2,353 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,000.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,757.81 | 2021-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $2,677.49 | 2021-2025 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals LP | $1,170.26 | 2022-2025 | Fasenra, Farxiga, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $784.71 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $442.21 | 2024-2025 | Tavneos |
| Actelion Pharmaceuticals US, INC. | $374.99 | 2023-2024 | Uptravi, Opsumit |
| Gilead Sciences, INC. | $330.66 | 2025 | Yeztugo |
| Horizon Therapeutics Plc | $251.05 | 2022-2023 | Krystexxa |
| Verona Pharma, INC. | $124.97 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $122.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.